OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours - PubMed
5 hours ago
- #GPCR engineering
- #solid tumors
- #CAR-NK therapy
- OR7A10 GPCR engineering enhances CAR-NK cell therapy for solid tumors.
- An in vivo CRISPR activation screen identified OR7A10 as a top candidate for improving CAR-NK cell efficacy.
- OR7A10-engineered CAR-NK cells showed improved proliferation, activation, and resistance in the tumor microenvironment.
- These engineered cells demonstrated strong in vivo efficacy across multiple solid tumor models.
- A 100% complete response was achieved in an orthotopic breast cancer mouse model.
- OR7A10-engineered CAR-NK cells offer a scalable, off-the-shelf therapeutic option for solid tumors.